Daniel D. Pinschewer
Founder bei Hookipa Biotech AG
Profil
Daniel D.
Pinschewer is the founder of Hookipa Biotech AG (2011) and HOOKIPA Pharma, Inc. (2011).
At HOOKIPA Pharma, Inc., he held the title of Chief Scientific Officer from 2017 to 2019.
Dr. Pinschewer's former jobs include being a Professor at the University of Basel and an Associate Professor at the University of Geneva from 2007 to 2013.
Dr. Pinschewer received his undergraduate degree from the University of Zurich Medical School.
Aktive Positionen von Daniel D. Pinschewer
| Unternehmen | Position | Beginn |
|---|---|---|
Hookipa Biotech AG
 Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | Founder | 01.07.2011 |
Ehemalige bekannte Positionen von Daniel D. Pinschewer
| Unternehmen | Position | Ende |
|---|---|---|
| HOOKIPA PHARMA INC. | Founder | 31.12.2019 |
| University of Geneva | Corporate Officer/Principal | 01.01.2013 |
| University of Basel | Corporate Officer/Principal | - |
Ausbildung von Daniel D. Pinschewer
| University of Zurich Medical School | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| HOOKIPA PHARMA INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Hookipa Biotech AG
Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | Health Technology |
